Olmesartán Vir (Olmesartan Medoxomil)

Olmesartan Medoxomil selectively blocks the angiotensin II type 1 (AT1) receptors on vascular smooth‑muscle cells, adrenal tissue, and renal tubules. This inhibition prevents angiotensin II‑mediated vasoconstriction, aldosterone release, and sodium‑water retention, leading to vasodilation, reduced blood volume, and a fall in systemic arterial pressure. The effect is sustained with once‑daily dosing.

The exact dose of Olmesartán Vir is determined by the prescribing clinician based on the patient’s blood‑pressure profile, age, renal function, and concomitant therapies. The prescriber may start with a low dose and titrate upward as needed to achieve target blood‑pressure goals, following local labeling and clinical guidelines.

Olmesartan Medoxomil is classified as pregnancy category D, indicating evidence of fetal risk and that it should be discontinued as soon as pregnancy is recognized. It is not recommended for use during breastfeeding because the drug may pass into breast milk. Women of child‑bearing potential should use effective contraception while on therapy.

To request Olmesartán Vir, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides a quotation that includes pricing, availability, shipping terms (including any cold‑chain requirements), and necessary import documentation.

Olmesartan belongs to the angiotensin II receptor blocker (ARB) class, which offers similar blood‑pressure control to ACE inhibitors but with a lower incidence of cough and angio‑edema. Compared with other ARBs such as losartan or valsartan, olmesartan provides a potent and long‑lasting effect, often allowing once‑daily dosing. Choice among agents depends on patient tolerance, comorbidities, and cost considerations.

Olmesartán Vir tablets should be stored at ambient temperature, preferably below 25 °C, in the original blister pack or container. Keep the medication away from moisture, direct sunlight, and excessive heat. Do not use the product after the expiry date, and keep it out of reach of children.

The medication is taken orally, usually once daily, with or without food. Tablets should be swallowed whole with a full glass of water and not be chewed, crushed, or split unless specifically instructed by a healthcare professional. Consistent timing each day helps maintain stable blood‑pressure control.

The most serious adverse reactions associated with Olmesartán Vir include angioedema (swelling of the face, lips, tongue, or throat), severe hypotension that can cause dizziness or fainting, acute kidney injury or worsening renal function, and hyperkalemia that may lead to cardiac arrhythmias. Patients should seek immediate medical attention if any of these symptoms occur.

Olmesartán Vir is contraindicated in patients with known hypersensitivity to olmesartan or any component of the formulation, in women who are pregnant, and in individuals with severe hepatic impairment. Caution is also advised for patients with bilateral renal artery stenosis, severe renal dysfunction, or those taking other drugs that significantly raise potassium levels. Consultation with a physician is required before initiating therapy.